We develop proprietary drugs in oncology, diabetology and pain utilizing unique formulations and drug delivery technologies

About BIOTTS

BIOTTS S.A., a Polish-American biotech company, develops proprietary drugs in oncology, diabetology, and pain utilizing unique formulations and drug delivery technologies. Biotts scientists have developed a breakthrough technology of universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). The properties of the carrier increase the bioavailability of active substances several times, enabling them to penetrate through the skin into soft tissues and bones. The carrier can be easily modified to obtain targeted action in pathologically changed tissues. Thanks to the system, it is possible to reduce the therapeutic dose of the drug while maintaining its original effect and simultaneously reducing the side effects. In addition, the system enables the transport of one to several active substances, which makes it possible to design multi-component drugs.

How does transdermal Biotts technology work:

Biotts scientists, with more than three decades of experience, develop proprietary drugs and transdermal systems, solve complex technological problems, and create effective solutions to help people around the world.

We have provided the market with a variety of solutions, including: non-aggregating nanocarrier used in the production of vitamin preparations, therapeutic gels, semi-solid forms of the drug: with a carrier of deep penetration and accelerating tissue regeneration.

A revolution in drug delivery